Pre-treatment with P2Y12inhibitors in ACS patients: who, when, why, and which agent?

Transition strategies from cangrelor to oral platelet P2Y12 receptor antagonists

(2016) David J. Schneider   CORONARY ARTERY DISEASE

Comparison of Ticagrelor Versus Prasugrel to Prevent Periprocedural Myonecrosis in Acute Coronary Syndromes

(2015) Laurent Bonello et al.   AMERICAN JOURNAL OF CARDIOLOGY

Pretreatment With Antiplatelet Drugs in Invasively Managed Patients With Coronary Artery Disease in the Contemporary Era: Review of the Evidence and Practice Guidelines

(2015) D. Capodanno et al.   Circulation-Cardiovascular Interventions

Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention

(2015) Dániel Aradi et al.   EUROPEAN HEART JOURNAL

2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

(2015) Marco Roffi et al.   EUROPEAN HEART JOURNAL

Predictors of bleeding in patients with acute coronary syndromes treated with prasugrel

(2015) Petr Widimsky et al.   HEART

Switching P2Y12-receptor inhibitors in patients with coronary artery disease

(2015) Fabiana Rollini et al.   Nature Reviews Cardiology

Prehospital administration of P2Y12 inhibitors and early coronary reperfusion in primary PCI: an observational comparative study

(2015) Hanna Ratcovich et al.   THROMBOSIS AND HAEMOSTASIS

Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION): study protocol for a randomized controlled trial

(2015) Jacek Kubica et al.   Trials

Pretreatment with P2Y 12 Inhibitors in Non–ST-Segment–Elevation Acute Coronary Syndrome: An Outdated and Harmful Strategy

(2014) Jean-Philippe Collet et al.   CIRCULATION

Pretreatment With P2Y 12 Inhibitors in Non–ST-Segment–Elevation Acute Coronary Syndrome Is Clinically Justified

(2014) Marco Valgimigli   CIRCULATION

2014 ESC/EACTS Guidelines on myocardial revascularization

(2014)   EUROPEAN HEART JOURNAL

2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes

(2014) Ezra A. Amsterdam et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Novel antiplatelet agents in acute coronary syndrome

(2014) Francesco Franchi et al.   Nature Reviews Cardiology

Prehospital Ticagrelor in ST-Segment Elevation Myocardial Infarction

(2014) Gilles Montalescot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents

(2014) Laura Mauri et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis

(2014) A. Bellemain-Appaix et al.   BMJ-British Medical Journal

2013 ESC guidelines on the management of stable coronary artery disease

(2013)   EUROPEAN HEART JOURNAL

Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data

(2013) Philippe Gabriel Steg et al.   LANCET

Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events

(2013) Deepak L. Bhatt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes

(2013) Gilles Montalescot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized Comparison of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome and Planned Invasive Strategy—Design and Rationale of the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 Trial

(2013) Stefanie Schulz et al.   Journal of Cardiovascular Translational Research

Third Universal Definition of Myocardial Infarction

(2012) Kristian Thygesen et al.   CIRCULATION

2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction

(2012) et al.   CIRCULATION

Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients with ST-Segment–Elevation Myocardial Infarction

(2012) Dimitrios Alexopoulos et al.   Circulation-Cardiovascular Interventions

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation

(2012) et al.   EUROPEAN HEART JOURNAL

Association of Clopidogrel Pretreatment With Mortality, Cardiovascular Events, and Major Bleeding Among Patients Undergoing Percutaneous Coronary Intervention

(2012) Anne Bellemain-Appaix et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Abciximab and Heparin versus Bivalirudin for Non–ST-Elevation Myocardial Infarction

(2011) Adnan Kastrati et al.   NEW ENGLAND JOURNAL OF MEDICINE

Platelet Aggregation and Its Association With Stent Thrombosis and Bleeding in Clopidogrel-Treated Patients

(2010) Dirk Sibbing et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Intravenous Platelet Blockade with Cangrelor during PCI

(2009) Deepak L. Bhatt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

(2009) Lars Wallentin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Platelet Inhibition with Cangrelor in Patients Undergoing PCI

(2009) Robert A. Harrington et al.   NEW ENGLAND JOURNAL OF MEDICINE

The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation

(2009) Jolanta M. Siller-Matula et al.   THROMBOSIS RESEARCH

Transitioning patients from cangrelor to clopidogrel: Pharmacodynamic evidence of a competitive effect

(2007) Steven R. Steinhubl et al.   THROMBOSIS RESEARCH